中文名稱(chēng):CID-5721353 | 英文名稱(chēng):CID-5721353 |
CAS:301356-95-6 | 品牌: 一研 |
保存條件: Store at -20°C | 產(chǎn)品類(lèi)別: 抑制劑 |
Cas : 301356-95-6 |
產(chǎn)品屬性:
產(chǎn)品名稱(chēng) | 規(guī)格 | CAS號(hào) | 型號(hào) |
CID-5721353 | 1mg 5mg 10mg 25mg | 301356-95-6 | EY-Y0165519 |
Cas No.301356-95-6
別名 N/A
化學(xué)名 N/A
分子式 C15H9BrN2O6S2
分子量 457.3
溶解度 Soluble in DMSO
儲(chǔ)存條件 Store at -20°C
General tips For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.
Shipping Condition Evaluation sample solution : ship with blue ice
All other available size: ship with RT , or blue ice upon request
產(chǎn)品描述:
BCL6 is a member of the BTB/POZ family of transcription factors. CID5721353 (Compound 79-6) specifically inhibits BCL6 repressor activity. CID5721353 disrupts BCL6 transcriptional complexes and reactivates BCL6 target genes. CID5721353 can specifically kill primary human DLBCL cells. Fifteen of 19 BCL6-positive cases (79%) display greater than 25% loss of viability in response to CID5721353 at 125 or 250 μM[1].
In order to test whether CID5721353 (Compound 79-6) can perform as an anti-lymphoma therapeutic agent in vivo, whether it can penetrate tumors after parenteral administration through a distal site is determined. For this purpose 107OCI-Ly7 cells are injected into the right flank of 10 SCID mice and allowed to form tumors. Once tumors reach ~1.5 grams, animals are injected IP with a single dose of 50 mg/kg of CID5721353 in 10% DMSO or vehicle (10% DMSO) and sacrificed at 0.5, 1, 1.5, 3, 6, 12 and 24 hours after CID5721353 administration. Blood and tumors are harvested. Quantitative HPLC/MS analysis of the serum shows that CID5721353 levels peak (to 55 μg/mL, which is equivalent to a 122 μM concentration) one hour after the IP injection. CID5721353 also reaches its highest peak (24.5 ng/mg) at the 1-hour time point in the tumors, and after a sharp decline in levels, decreases gradually over 24 hours[1].
Reference:
[1]. Cerchietti LC, et al. A small-molecule inhibitor of BCL6 kills DLBCL cells in vitro and in vivo. Cancer Cell. 2010 Apr 13;17(4):400-11.
成立日期 | 2014-06-05 (11年) | 注冊(cè)資本 | 100 |
員工人數(shù) | 50-100人 | 年?duì)I業(yè)額 | ¥ 100萬(wàn)以內(nèi) |
主營(yíng)行業(yè) | 生化試劑,抗體,細(xì)胞培養(yǎng),分子生物學(xué),免疫安全 | 經(jīng)營(yíng)模式 | 工廠,試劑 |
產(chǎn)品名稱(chēng) | 價(jià)格 | 公司名稱(chēng) | 報(bào)價(jià)日期 | |
---|---|---|---|---|
詢價(jià) |
VIP6年
|
成都彼樣生物科技有限公司
|
2025-01-10 | |
¥169 |
VIP3年
|
TargetMol中國(guó)(陶術(shù)生物)
|
2024-12-12 | |
¥2664.90 |
VIP1年
|
上海阿拉丁生化科技股份有限公司
|
2024-11-29 |